Bone mineral content of women receiving tamoxifen for mastalgia

Bone mineral content of women receiving tamoxifen for mastalgia

Play all audios:

Loading...

ABSTRACT Dual photon absorptiometry (DPA) has been used to measure the effect of short and medium-term administration of tamoxifen on bone density in the axial skeleton of women with mastalgia. This provided a unique opportunity to monitor the effect of this 'anti-oestrogenic' agent in predominantly premenopausal women, not suffering from malignancy. In addition, plasma levels of calcium, phosphate, alkaline phosphatase and serum levels of oesteocalcin (GLA) have been assayed, both before and after 3 months of starting either tamoxifen or placebo treatment. No significant alterations in bone density were seen. Osteocalcin, alkaline phosphatase and electrolytes were unchanged and there was no dose response observed in women receiving either 10 mg or 20 mg of tamoxifen. Although possessing anti-oestrogenic properties, tamoxifen is also a partial agonist. Administration for the short periods does not measurably influence spinal or femoral bone density and thus the agent can probably be given safely for the short-term treatment of mastalgia. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS BONE MINERAL DENSITY IN WOMEN NEWLY DIAGNOSED WITH BREAST CANCER: A PROSPECTIVE COHORT STUDY Article Open access 17 February 2022 STEROID HORMONE LEVELS AND BONE MINERAL DENSITY IN WOMEN OVER 65 YEARS OF AGE Article Open access 25 March 2023 BONE HEALTH IN NEWLY DIAGNOSED FEMALE BREAST CANCER PATIENTS IN CHINA: A CROSS-SECTIONAL STUDY Article Open access 01 February 2025 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Clinical Oncology, Guy's Hospital, London, UK IS Fentiman Authors * IS Fentiman View author publications You can also search for this author inPubMed Google Scholar * M Caleffi View author publications You can also search for this author inPubMed Google Scholar * A Rodin View author publications You can also search for this author inPubMed Google Scholar * B Murby View author publications You can also search for this author inPubMed Google Scholar * I Fogelman View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Fentiman, I., Caleffi, M., Rodin, A. _et al._ Bone mineral content of women receiving tamoxifen for mastalgia. _Br J Cancer_ 60, 262–264 (1989). https://doi.org/10.1038/bjc.1989.266 Download citation * Issue Date: 01 August 1989 * DOI: https://doi.org/10.1038/bjc.1989.266 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative

ABSTRACT Dual photon absorptiometry (DPA) has been used to measure the effect of short and medium-term administration of tamoxifen on bone density in the axial skeleton of women with


mastalgia. This provided a unique opportunity to monitor the effect of this 'anti-oestrogenic' agent in predominantly premenopausal women, not suffering from malignancy. In


addition, plasma levels of calcium, phosphate, alkaline phosphatase and serum levels of oesteocalcin (GLA) have been assayed, both before and after 3 months of starting either tamoxifen or


placebo treatment. No significant alterations in bone density were seen. Osteocalcin, alkaline phosphatase and electrolytes were unchanged and there was no dose response observed in women


receiving either 10 mg or 20 mg of tamoxifen. Although possessing anti-oestrogenic properties, tamoxifen is also a partial agonist. Administration for the short periods does not measurably


influence spinal or femoral bone density and thus the agent can probably be given safely for the short-term treatment of mastalgia. Access through your institution Buy or subscribe This is a


preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per


year only $10.79 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated


during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS BONE MINERAL


DENSITY IN WOMEN NEWLY DIAGNOSED WITH BREAST CANCER: A PROSPECTIVE COHORT STUDY Article Open access 17 February 2022 STEROID HORMONE LEVELS AND BONE MINERAL DENSITY IN WOMEN OVER 65 YEARS OF


AGE Article Open access 25 March 2023 BONE HEALTH IN NEWLY DIAGNOSED FEMALE BREAST CANCER PATIENTS IN CHINA: A CROSS-SECTIONAL STUDY Article Open access 01 February 2025 AUTHOR INFORMATION


AUTHORS AND AFFILIATIONS * Department of Clinical Oncology, Guy's Hospital, London, UK IS Fentiman Authors * IS Fentiman View author publications You can also search for this author


inPubMed Google Scholar * M Caleffi View author publications You can also search for this author inPubMed Google Scholar * A Rodin View author publications You can also search for this


author inPubMed Google Scholar * B Murby View author publications You can also search for this author inPubMed Google Scholar * I Fogelman View author publications You can also search for


this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Fentiman, I., Caleffi, M., Rodin, A. _et al._ Bone mineral content of


women receiving tamoxifen for mastalgia. _Br J Cancer_ 60, 262–264 (1989). https://doi.org/10.1038/bjc.1989.266 Download citation * Issue Date: 01 August 1989 * DOI:


https://doi.org/10.1038/bjc.1989.266 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not


currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative